Articles
Don't overlook what’s underfoot - save the bugs and germs
One of the biggest problems for conservation today is that it ignores 95% of all known species on Earth. Could a company ignore that proportion of its clients or a government so many of its voters? So why does this problem exist in conservation? [ + ]
Regeneus, Cryosite sign stem cell alliance
Regeneus (ASX:RGS) and Cryosite (ASX:CTE) have agreed to share technology and expertise in the area of stem cell products for human applications. [ + ]
Sirtex profit grows 30% in FY14
Sirtex Medical (ASX:SRX) has posted a 30.6% increase in profit for FY14, as dose sales of its SIR-Spheres liver cancer treatment reached a record high. [ + ]
Personalised, predictive, preventive and participatory
The upcoming Annual Scientific Conference of the Australasian Association of Clinical Biochemists (AACB) will focus on Clinical Biochemistry Supporting P4 Medicine - the four 'Ps' representing personalised, predictive, preventive and participatory. [ + ]
Turn a $40 needle into a 3D microscope
Researchers from the University of Utah have discovered a method for turning a small, $40 needle into a 3D microscope capable of taking images up to 70 times smaller than the width of a human hair. [ + ]
Forensic provenance: the science of art authentication
The value of an artwork can vary by orders of magnitude if its provenance can be established; increasingly, science is coming to the aid of curators to prove provenance. [ + ]
Lead site for Innate's SPMS trial wins ethics nod
Innate Immunotherapeutics (ASX:IIL) announced that WANRI - lead site for its phase IIb trial of MIS416 in secondary progressive multiple sclerosis - has been cleared to start recruiting patients. [ + ]
QRxPharma abandons MoxDuo development
QRxPharma (ASX:QRX) has ceased development of dual-opioid drug MoxDuo, after the board decided that the cost of additional trials sure to be required for US approval could not be justified. [ + ]
Fund R&D, then maybe universities can support industry
Industry Minister Ian Macfarlane let his discretion slip this week in a speech to the Queensland Media Club when foreshadowing an upcoming report on research funding and competition. Distancing himself from the awarding of funding based on prior researcher publications, he signalled a distinctly different approach that is likely to inform policy in the near future. [ + ]
There are no free rides to the future: Australia's Chief Scientist
This is a transcript of the 2014 Jack Beale Lecture on the Global Environment, hosted at the University of New South Wales. [ + ]
CSL's FY14 profit grows 8% to $1.4bn
CSL (ASX:CSL) has reported an 8% growth in FY14 profit, despite the impact of a legal settlement and a decline in sales at its bioCSL division. [ + ]
Bespoke biotech
Additive manufacturing and 3D printing technology have a lot to offer makers of biomedical devices. [ + ]
Genomics API allowing for seamless sharing of genetic data
The Global Alliance for Genomics and Health has announced a new application programming interface that will allow DNA data providers and consumers to better share information and work together on a global scale. [ + ]
Phosphagenics completes IND-enabling pain patch study
Phosphagenics (ASX:POH) achieved encouraging results from the first of two planned IND-enabling phase I trials of pain patch TPM/oxymorphone. [ + ]
World-first computer chip inspired by the human brain
Scientists from IBM have unveiled the first neurosynaptic computer chip to achieve an unprecedented scale of 1 million programmable spiking neurons, 256 million programmable synapses and 46 billion synaptic operations per second per watt. [ + ]
